Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-15

Study Completion Date

2022-10-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate how safe Budigalimab is and how it moves within the body in adult participants with HIV-1 infection.

Budigalimab is an investigational drug being evaluated for the treatment of Human Immunodeficiency Virus. Study participants will be assigned to one of the 4 treatment groups and will receive a single dose of Budigalimab or placebo subcutaneous (SC) and intravenous (IV). Around 32 participants 18-65 years of age living with Human Immunodeficiency Virus will be enrolled in the study in approximately 9 sites worldwide.

Each participant will receive single dose of SC and IV Budigalimab and/or Placebo on day 1 and will be followed for 24 weeks.

Participants will attend weekly to every two and every four weeks visits during the study at a hospital. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects. There may be higher treatment burden for participants in this trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

NCT04554966

Human Immunodeficiency Virus (HIV)

COMPLETED PHASE1

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

NCT00002353

HIV Infections

COMPLETED PHASE1

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

NCT02028403

HIV Infections

COMPLETED PHASE1

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

NCT00059462

HIV Infections

COMPLETED PHASE1/PHASE2

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects

NCT00000845

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Immunodeficiency Virus (HIV)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: Placebo SC + Placebo IV

Participants will receive Subcutaneous (SC) Placebo, followed by Intravenous (IV) Placebo.

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Subcutaneous (SC)

Placebo

Intervention Type DRUG

Intravenous (IV)

Group 2: Budigalimab (SC) + Placebo IV

Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.

Group Type EXPERIMENTAL

Budigalimab

Intervention Type DRUG

Subcutaneous (SC)

Placebo

Intervention Type DRUG

Intravenous (IV)

Group 3: Budigalimab SC + Placebo IV

Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.

Group Type EXPERIMENTAL

Budigalimab

Intervention Type DRUG

Subcutaneous (SC)

Placebo

Intervention Type DRUG

Intravenous (IV)

Group 4: Placebo SC + Budigalimab IV

Participants will receive Subcutaneous (SC) Placebo, followed by IV Budigalimab.

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Subcutaneous (SC)

Budigalimab

Intervention Type DRUG

Intravenous (IV)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Budigalimab

Subcutaneous (SC)

Intervention Type DRUG

Placebo

Subcutaneous (SC)

Intervention Type DRUG

Budigalimab

Intravenous (IV)

Intervention Type DRUG

Placebo

Intravenous (IV)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABBV-181 ABBV-181

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Condition of generally good health, body mass index ≥ 18.0 to \< 35.0 kg/m2.
* Laboratory values must meet acceptable criteria.
* Human Immunodeficiency Virus (HIV-1) infected on antiretroviral therapy (ART) for at least 12 months prior to screening and on current ART regimen for at least 8 weeks prior to screening.
* CD4 cell count ≥ 450 cells/μL at Screening and during the 12 months prior to Screening.
* Plasma HIV-1 RNA below the lower limit of quantification at Screening and at least 6 months prior to Screening.
* Participants agreeing to use an effective barrier method of protection (male and/or female condom) during sexual activity from Study Day 1 through last study visit for the purposes of prevention of HIV transmission.

Exclusion Criteria

* Participants with signs/symptoms associated with SARS-CoV-2 infection OR Current SARS-CoV-2 infection by any viral nucleic acid test completed within 7 days prior to the Day 1 dose.
* Participants having history or ongoing diagnosis of acquired immunodeficiency syndrome (AIDS)-defining illness.
* Participants having history of or active immunodeficiency (other than HIV).
* Participants having active autoimmune disease or history of autoimmune disease that has required systemic treatment.
* Prior therapy/exposure to budigalimab or any other immune checkpoint inhibitor \[e.g., anti-programmed cell death protein 1(PD-1), anti-PD-L1, anti-PD-L2, anti-CTLA4\].
* Participants having clinically significant medical disorders that might expose the subjects to undue risk of harm, confound study outcomes, or prevent the subject from completing the study.
* Participants having active or suspected malignancy or history of malignancy (other than basal cell skin cancer or cervical carcinoma in situ) in the past 5 years.
* Participants with history of or active tuberculosis (TB) at screening.
* Participants having known psychiatric or substance abuse disorders that would interfere with adherence to study requirements.
* Participants who have received immunomodulatory or immunosuppressive (including IV/orally administered \[PO\] steroids at any dose, but excluding steroids that are inhaled, topical or via local injection) therapy within 24 weeks prior to the first dose of study drug.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No